Open Interest and Volume Spike
The latest data reveals that Mankind Pharma’s open interest (OI) in derivatives jumped from 18,126 contracts to 26,432, marking a robust increase of 8,306 contracts or 45.82% on 31 Jul 2026. This surge in OI accompanies a total traded volume of 50,844 contracts, underscoring a pronounced uptick in market participation compared to previous sessions.
In monetary terms, the futures segment alone accounted for a value of approximately ₹47,886 lakhs, while options contracts contributed an enormous ₹27,639 crores, culminating in a combined derivatives turnover of ₹53,455 lakhs. Such figures highlight the growing interest in Mankind Pharma’s derivatives, despite the underlying stock’s recent underperformance.
Price Action and Volatility Context
Mankind Pharma’s stock price has been under pressure, declining by 4.55% on the day and underperforming its sector by 5.22%. The stock has now recorded three consecutive days of losses, cumulatively falling 6.07%. Intraday volatility was elevated at 6.23%, with the stock touching a low of ₹2,422, nearly 6% below its previous close. Notably, the weighted average price of traded shares skewed closer to the day’s low, indicating selling pressure.
Despite this short-term weakness, the stock remains above its 100-day and 200-day moving averages, though it trades below the 5-day, 20-day, and 50-day averages. This technical positioning suggests a mixed trend, with longer-term support intact but near-term momentum waning.
Investor Participation and Liquidity
Delivery volumes have slightly declined, with 1.67 lakh shares delivered on 30 Jul, down 0.47% against the five-day average. However, liquidity remains adequate, supporting trade sizes up to ₹1.8 crore based on 2% of the five-day average traded value. This level of liquidity facilitates active trading in both the cash and derivatives markets.
Patience pays off here! This Micro Cap from Fertilizers sector has delivered steady gains quarter after quarter. Now proudly part of our Reliable Performers list.
- - New Reliable Performer
- - Steady quarterly gains
- - Fertilizers consistency
Market Positioning and Directional Bets
The sharp rise in open interest alongside elevated volumes suggests that traders are actively repositioning in Mankind Pharma’s derivatives. The increase in OI typically indicates fresh capital entering the market, either through new long or short positions. Given the stock’s recent price decline and heightened volatility, it is plausible that market participants are hedging existing exposures or speculating on a potential rebound or further correction.
Options data, with a massive notional value exceeding ₹27,639 crores, points to significant activity in calls and puts. This could reflect a range of strategies, from protective puts to speculative call buying or selling. The large futures value of ₹47,886 lakhs further confirms that institutional players may be taking sizeable directional stances.
Mojo Score Upgrade and Analyst Sentiment
Mankind Pharma’s Mojo Score currently stands at 72.0, earning it a Buy grade, upgraded from Hold on 29 Jul 2026. This upgrade reflects improved fundamentals and positive outlook from MarketsMOJO analysts, who classify the company as a mid-cap pharmaceutical player with solid growth prospects. The rating change may have contributed to increased investor interest and derivative market activity.
However, the recent price weakness and volatility caution investors to monitor technical levels closely. The stock’s underperformance relative to the sector and Sensex (which gained 0.76% and 0.19% respectively on the day) indicates some near-term headwinds, possibly linked to broader market sentiment or sector-specific developments.
Want to dive deeper on Mankind Pharma Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Implications for Investors
The surge in open interest and volume in Mankind Pharma’s derivatives market signals a pivotal moment for investors. While the stock’s recent price decline and volatility may deter some, the increased market activity suggests that sophisticated traders are positioning for a directional move. Investors should consider the stock’s technical support levels, sector dynamics, and the upgraded Mojo rating when evaluating their exposure.
Given the pharmaceutical sector’s inherent cyclicality and regulatory sensitivities, monitoring derivative market trends can provide valuable insights into institutional sentiment and potential price trajectories. The current data points to a cautious but opportunistic environment, where both bulls and bears are actively engaged.
Summary
Mankind Pharma Ltd’s derivatives market has experienced a notable open interest surge of 45.82%, accompanied by high volumes and significant monetary turnover. Despite a short-term price correction and elevated volatility, the company’s upgraded Mojo Score and mid-cap status underpin a positive medium-term outlook. Market participants are evidently recalibrating positions, making the stock a focal point for active traders and investors seeking exposure to the pharmaceuticals & biotechnology sector.
As always, investors should weigh the risks associated with volatility and market sentiment shifts, using derivative market data as a complementary tool to fundamental and technical analysis.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
